Crossmark

The component of the m6A writer complex VIRMA is implicated in aggressive tumor phenotype, DNA damage response and cisplatin resistance in germ cell tumors

Crossref DOI link: https://doi.org/10.1186/s13046-021-02072-9

Published Online: 2021-08-25

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Miranda-Gonçalves, Vera https://orcid.org/0000-0002-4231-5532
Lobo, João https://orcid.org/0000-0001-6829-1391
Guimarães-Teixeira, Catarina https://orcid.org/0000-0003-2212-3872
Barros-Silva, Daniela https://orcid.org/0000-0001-6746-6807
Guimarães, Rita

Cantante, Mariana

Braga, Isaac

Maurício, Joaquina

Oing, Christoph https://orcid.org/0000-0001-5578-3418
Honecker, Friedemann

Nettersheim, Daniel https://orcid.org/0000-0002-4483-845X
Looijenga, Leendert H. J. https://orcid.org/0000-0002-8146-1911
Henrique, Rui https://orcid.org/0000-0003-3171-4666
Jerónimo, Carmen https://orcid.org/0000-0003-4186-5345
Funding

Funding for this research was provided by:

Fundação para a Ciência e a Tecnologia (PTDC/MEC-URO/ 29043/2017, SFRH/BD/132751/2017, DFA/BD/6038/2020, SFRH/BD/136007/2018)
License Information

Text and Data Mining valid from 2021-08-25

Version of Record valid from 2021-08-25
More Information

Article History

Received: 27 April 2021

Accepted: 11 August 2021

First Online: 25 August 2021

Declarations

:

: This study was approved by the Ethics Committee (CES-IPO-1/018) of Portuguese Oncology Institute of Porto, Portugal. All procedures performed in tasks involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below